GHK-Cu (cognitive angle)
Also known as: Gly-His-Lys-Cu · Copper tripeptide-1
A naturally occurring tripeptide-copper complex best known for skin and tissue-repair effects, but with a distinct cognitive-research literature covering gene-expression modulation, antioxidant defence, and indirect neurotrophic effects.
GHK-Cu is a copper-binding tripeptide (Gly-His-Lys) with gene-expression, wound-healing, and emerging neuroprotective effects; injected or topically applied.
Evidence tier: B — clinical evidence (trials or approved use in some jurisdictions)
- Category
- Neurogenesis
- Half-life
- Short plasma half-life; gene-expression effects persist beyond clearance
- Formula
- C₁₄H₂₄N₆O₄Cu (as Cu complex)
- Weight
- 402.93 g/mol (Cu complex)
- Sequence
- Gly-His-Lys (with bound Cu²⁺)
Section 1
Overview
GHK-Cu is a naturally occurring tripeptide — glycine-histidine-lysine — that complexes copper ions in plasma and tissue. The molecule was first isolated in the 1970s as the factor in young human plasma that supported wound healing more effectively than the same plasma from older donors. Its predominant identity in the research-peptide market is as a skin and tissue-repair compound, but it has a distinct and less-publicised literature on cognitive and brain-tissue effects.
The cognitive case for GHK-Cu rests on three observations. First, the molecule has been characterised as a broad-spectrum modulator of gene expression — published gene-array work suggests it shifts expression of more than a thousand genes toward a youthful phenotype, including a substantial number in pathways relevant to neuronal survival, antioxidant defence, and neurotrophic signalling. Second, copper homeostasis is itself relevant to CNS function: dysregulated copper handling is implicated in several neurodegenerative conditions. Third, animal research has reported antioxidant and neuroprotective effects in brain-tissue preparations.
The cognitive evidence base is meaningfully smaller than the skin-and-tissue-repair evidence base. GHK-Cu is included on this site for completeness — it is studied in cognitive contexts in the published research-peptide literature — with the caveat that the strongest evidence for the molecule lies outside the cognitive endpoint.
Section 2
Discovery & History
- Isolated by Loren Pickart and colleagues in 1973 as the active factor in young human plasma that supported wound healing more effectively than the same plasma from older donors — one of the earliest identified 'youth factor' molecules.
- Initial characterisation through the 1970s and 1980s focused on wound healing, tissue regeneration, and copper-transport pharmacology; cognitive and brain-tissue effects were investigated more sporadically thereafter.
- Widely adopted in cosmetic skin-care formulations from the 1990s onwards under the cosmetic-ingredient regulatory framework, distinct from the medicinal-product pathway. This is the compound's dominant commercial identity.
- Cognitive and gene-expression research has continued in academic and independent contexts, generating the broader 'pleiotropic regulator' framing under which the molecule is now described — supported particularly by the 2010s gene-array work.
- The distinctive dual identity — commercial cosmetic ingredient and research-cognitive peptide — creates a distinctive sourcing landscape that requires careful attention to material grade.
Section 3
Mechanism of Action
- 1Broad gene-expression modulation — published microarray research reports shifts in expression of over 1,000 genes toward a youthful or pro-repair phenotype across multiple tissue types, with the shift disproportionately affecting antioxidant defence, DNA repair, and neurotrophic-signalling pathways.
- 2Copper-dependent enzymatic effects — GHK-Cu delivers copper to tissues in a bioavailable form, supporting the function of copper-dependent enzymes including superoxide dismutase 1/3 (antioxidant defence), lysyl oxidase (extracellular matrix remodelling), and dopamine β-hydroxylase (catecholamine synthesis).
- 3Antioxidant effects via upregulation of endogenous antioxidant enzyme expression (superoxide dismutase, catalase, glutathione peroxidase) and direct radical-scavenging by the copper-peptide complex at physiological pH.
- 4Reported neuroprotective effects in animal models of cerebral ischaemia and excitotoxic injury — attributed to combined antioxidant, anti-inflammatory, and possibly mild neurotrophic mechanisms operating through the gene-expression changes.
- 5Modulation of inflammatory gene expression — measurable reductions in pro-inflammatory markers (TNF-α, IL-1β, NF-κB activation) in tissue-injury models, providing a mechanism-of-action angle for the neuroprotective claims.
- 6Restoration of youthful gene-expression patterns in aged tissue — the most-distinctive finding in the GHK-Cu literature and the mechanism-of-action root for the broader 'anti-ageing' positioning of the molecule.
- 7Angiogenic effects — increased vascular endothelial growth factor (VEGF) expression and modest neovascularisation in tissue-repair contexts, plausibly contributing to neuroprotection in cerebral-ischaemia settings.
Section 4
Researched Benefits
Findings reported in the published preclinical and clinical literature. Effects in research contexts do not constitute claims of therapeutic benefit in humans.
- 1Antioxidant and tissue-protective effects in brain-tissue preparations under oxidative challenge — the most-directly-cognitive-relevant benefit and the one with the strongest mechanistic scaffold.
- 2Broad pro-repair gene-expression signature relevant to ageing-related cognitive decline contexts — the transcriptional-programme angle that distinguishes GHK-Cu from single-target peptides.
- 3Reported neuroprotective effects in animal models of CNS injury, particularly cerebral ischaemia and excitotoxic damage.
- 4Copper-delivery role supporting endogenous antioxidant enzyme function — provides bioavailable copper without the peripheral toxicity risks of ionic copper administration.
- 5Naturally occurring molecule with extensive non-cognitive safety record from cosmetic use, providing a partial safety floor unusual for a research peptide.
- 6Angiogenic effects that may contribute to cognitive-endpoint benefits in cerebrovascular-relevant contexts, alongside the direct antioxidant and gene-expression effects.
- 7Compatibility with the broader Khavinson-bioregulator conceptual framework — GHK-Cu is often studied alongside Pinealon and Epitalon in ageing-cognition research designs.
Section 5
Theoretical Dosing & Protocols
| Route | Dosage | Frequency | Duration |
|---|---|---|---|
| Subcutaneous / intranasal (research) | Microgram to milligram range in animal protocols | Daily during a course | Variable across published protocols |
Note: Topical GHK-Cu (cosmetic preparations) is a separate product category; the cognitive-research material is distinct.
Section 6
Administration Routes
- Subcutaneous injection — primary route in animal research.
- Intranasal administration documented in some research protocols.
- Topical application is the dominant route for skin-care applications, not the cognitive research literature.
- Oral administration faces the standard peptide-degradation barrier.
Section 7
Safety Profile
Commonly reported
- · Generally well-tolerated in animal research and in the substantial cosmetic-use safety record — the extensive tissue-repair pharmacovigilance database extends the confidence in acute tolerability.
- · Mild local reactions at injection or topical-application site occasionally reported — transient erythema, mild tenderness, or minor irritation.
- · Occasional mild flushing sensation during subcutaneous administration in some subjects, resolving within minutes.
- · Rare reports of transient dysgeusia (metallic taste) with intranasal administration, related to the copper component.
Rare / theoretical
- · Copper toxicity is theoretically possible with excessive systemic administration; the standard research doses are far below relevant toxicity thresholds, but chronic high-dose administration has not been formally evaluated for cumulative copper burden.
- · The cognitive-research safety literature specifically is sparser than the general (cosmetic and tissue-repair) safety record.
- · Long-term effects of chronic systemic GHK-Cu administration in cognitive contexts are uncharacterised — the reported studies are short-course.
- · Theoretical interaction with zinc-supplement medications given the copper-zinc antagonism at absorption and cellular level.
Contraindications
- · Not authorised for human medicinal use in the UK — supply for human consumption is prohibited under the Human Medicines Regulations 2012, though cosmetic-grade material is regulated under a separate framework.
- · Pregnancy and lactation — limited controlled data.
- · Wilson's disease and other copper-metabolism disorders — relative contraindication via the copper component of the molecule.
- · Concurrent penicillamine or trientine therapy for copper-metabolism disorders — pharmacodynamic incompatibility.
Section 8
UK & EU Regulatory Context
United Kingdom
Not licensed as a medicine in the UK. Research chemical only; some cosmetic-grade GHK-Cu is sold for topical use, distinct from research-grade material.
European Union
Not approved by the EMA as a medicine. Used in cosmetic formulations under separate regulatory framework.
Section 9
Clinical Studies Summary
GHK-Cu gene-expression effects in human fibroblast cultures
Genome-wide microarray analysis of human fibroblasts exposed to GHK-Cu, demonstrating modulation of expression of over 1,000 genes with the modulation pattern aligning with a shift toward a younger transcriptional phenotype across antioxidant, DNA-repair, and growth-factor pathways. The flagship gene-expression study that positioned GHK-Cu as a broad-spectrum transcriptional regulator rather than a single-target compound.
Neuroprotective effects of GHK-Cu in cerebral ischaemia models
Rodent model of middle-cerebral-artery-occlusion cerebral ischaemia with pre- and post-injury GHK-Cu administration, reporting reduced infarct volume, improved neurological deficit scoring, and preserved histological outcome in the treated cohort versus vehicle controls, attributed to combined antioxidant and anti-inflammatory mechanisms.
Antioxidant enzyme modulation by GHK-Cu in brain tissue
Biochemistry study demonstrating upregulation of superoxide dismutase and catalase expression in brain tissue following GHK-Cu administration in a rodent oxidative-stress model, supporting the antioxidant-defence pathway as one of the molecule's principal neuroprotective routes.
GHK-Cu in age-related cognitive decline models
Behavioural pharmacology study in aged rats receiving chronic GHK-Cu administration, reporting preserved learning performance on hippocampus-dependent tasks, improved hippocampal antioxidant status, and gene-expression profiles suggestive of restored youthful transcriptional patterns in the treated cohort.
GHK-Cu angiogenic effects in cerebrovascular context
Vascular biology study reporting increased VEGF expression, endothelial-cell migration, and modest neovascularisation in the peri-infarct zone following GHK-Cu administration in cerebral-ischaemia recovery models, extending the mechanism-of-action angle beyond the direct antioxidant effect.
Section 10
Frequently Asked Questions
Section 10a
Practical Research Guidance
Cycle guidance
Reconstitution & storage
UK sourcing notes
Section 11
Sourcing for Laboratory Research
Sourcing GHK-Cu (cognitive angle) for laboratory research
Researchers in the United Kingdom and elsewhere typically obtain GHK-Cu (cognitive angle) from specialist research-chemical suppliers. Purity, third-party testing, and supplier transparency are the principal differentiators worth evaluating before placing an order. The two suppliers below are commonly referenced in UK research contexts.
Reminder: research peptides are sold strictly for in vitro and preclinical laboratory purposes. Importation or supply for human consumption is not permitted under UK medicines legislation.